Scholar Rock Holding Corporation
SRRK
Pozycja w akcjach
#3430
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Cena akcji
$41.52
Kapitalizacja rynkowa
$5.06B
Zmiana (1 dzień)
3.18%
Zmiana (1 rok)
48.71%
Kraj
US
Handel Scholar Rock Holding Corporation (SRRK)
Kategoria
Healthcare
Zyski dla Scholar Rock Holding Corporation (SRRK)
Zyski w Jun 2026 TTM: $-408.59M
Według najnowszych raportów finansowych Scholar Rock Holding Corporation, obecny zysk firmy wynosi $-408.59M. W roku 2023 firma osiągnęła zysk w wysokości $-165.79M, spadek w porównaniu do zysku z roku 2022, który wynosił $-134.50M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Scholar Rock Holding Corporation od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-408.59M | 65.90% |
| 2024 | $-246.29M | 48.56% |
| 2023 | $-165.79M | 23.26% |
| 2022 | $-134.50M | 2.05% |
| 2021 | $-131.80M | 52.40% |
| 2020 | $-86.48M | 69.57% |
| 2019 | $-51.00M | 3.39% |
| 2018 | $-49.33M | 97.34% |
| 2017 | $-25.00M | 54.22% |
| 2016 | $-16.21M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -1,391.00% |
US
|
|
| $-3.09B | 655.52% |
US
|
|
| $-4.02B | 882.94% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -577.41% |
NL
|
